| 000 | 01542 a2200397 4500 | ||
|---|---|---|---|
| 005 | 20250518094731.0 | ||
| 264 | 0 | _c20210304 | |
| 008 | 202103s 0 0 eng d | ||
| 022 | _a2210-7711 | ||
| 024 | 7 |
_a10.1007/s11096-020-01018-z _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aNeha, Reddy | |
| 245 | 0 | 0 |
_aAromatase inhibitors associated osteonecrosis of jaw: signal refining to identify pseudo safety signals. _h[electronic resource] |
| 260 |
_bInternational journal of clinical pharmacy _cApr 2020 |
||
| 300 |
_a721-727 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdverse Drug Reaction Reporting Systems |
| 650 | 0 | 4 |
_aAromatase Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aBisphosphonate-Associated Osteonecrosis of the Jaw _xdiagnosis |
| 650 | 0 | 4 |
_aDiphosphonates _xadministration & dosage |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFalse Positive Reactions |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aJaw Diseases _xchemically induced |
| 650 | 0 | 4 |
_aOsteonecrosis _xchemically induced |
| 650 | 0 | 4 | _aPharmacovigilance |
| 650 | 0 | 4 |
_aUnited States _xepidemiology |
| 650 | 0 | 4 |
_aUnited States Food and Drug Administration _xstandards |
| 700 | 1 | _aBeulah, Elsa | |
| 700 | 1 | _aAnusha, Bellapu | |
| 700 | 1 | _aVasista, Sharma | |
| 700 | 1 | _aStephy, Chacko | |
| 700 | 1 | _aSubeesh, Viswam | |
| 773 | 0 |
_tInternational journal of clinical pharmacy _gvol. 42 _gno. 2 _gp. 721-727 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s11096-020-01018-z _zAvailable from publisher's website |
| 999 |
_c30837701 _d30837701 |
||